Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Technology appraisal
Reference number: TA976
Published:
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-July 2024. The appraisal timings will ensure the company is able to make a suitably comprehensive and robust submission.